Biogen Inc. (BIIB) Q1 2026 (USD): Adj. EPS 3.57 (exp. 2.99), Revenue 2.5bln (exp. 2.25bln); sees FY Adj. EPS 14.20-15.25 (exp. 15.46, prev. saw 15.25-16.25)
Importance
Level 1
- Updated guidance includes an approximately USD 1.00 impact from acquired IPR&D charges resulting from ongoing business development activities to support Biogen's growth strategy